Literature DB >> 23346877

Pretransplant model for end stage liver disease score predicts posttransplant incidence of fungal infections after liver transplantation.

Christoph Lichtenstern1, Marcel Hochreiter, Verena D Zehnter, Thorsten Brenner, Stefan Hofer, Markus Mieth, Markus W Büchler, Eike Martin, Markus A Weigand, Peter Schemmer, Cornelius J Busch.   

Abstract

Liver transplant recipients are at a significant risk for invasive fungal infections (IFI). This retrospective study evaluated the impact of the pretransplant model for end stage liver disease (MELD) on the incidence of posttransplant IFI in a single centre. From 2004 to 2008, 385 liver transplantations were included, from which 210 transplantations were conducted allocated by Child Turcotte Pugh and 175 were allocated by MELD score. Both groups differed regarding the age of transplant recipients (50.1 ± 10.7 vs. 52.5 ± 9.9, P = 0.036), pretransplant MELD score (16.43 ± 8.33 vs. 18.29 ± 9.05), rate of re-transplantations, duration of surgery, demand in blood transfusions and rates of renal impairments. In the MELD era, higher incidences of IFI (pre-MELD 11.9%, MELD 24.0%, P < 0.05) and Candida infections (9% vs. 18.9%, P < 0.05) were observed. There was no difference in the incidence of probable or possible aspergillosis. Mortality, length of stay in intensive care or hospital, and duration of mechanical ventilation did not differ between the pre-MELD and MELD era. Regardless the date of transplantation, patients with fungi-positive samples showed higher mortality rates than patients without. MELD score was analysed as independent predictors for posttransplant IFI. Higher MELD scores predispose to a more problematic postoperative course and are associated with an increase in fungal infections.
© 2013 Blackwell Verlag GmbH.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23346877     DOI: 10.1111/myc.12041

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  3 in total

1.  Targeted versus universal antifungal prophylaxis among liver transplant recipients.

Authors:  G A Eschenauer; E J Kwak; A Humar; B A Potoski; L G Clarke; R K Shields; R Abdel-Massih; F P Silveira; P Vergidis; C J Clancy; M H Nguyen
Journal:  Am J Transplant       Date:  2014-10-30       Impact factor: 8.086

2.  Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients.

Authors:  Faouzi Saliba; Andreas Pascher; Olivier Cointault; Pierre-François Laterre; Carlos Cervera; Jan J De Waele; Umberto Cillo; Róbert M Langer; Manuela Lugano; Bo Göran-Ericzon; Stephen Phillips; Lorraine Tweddle; Andreas Karas; Malcolm Brown; Lutz Fischer
Journal:  Clin Infect Dis       Date:  2014-12-17       Impact factor: 9.079

3.  Effect of delayed CNI-based immunosuppression with Advagraf® on liver function after MELD-based liver transplantation [IMUTECT].

Authors:  Susanne Richter; Georg Polychronidis; Daniel N Gotthardt; Philipp Houben; Thomas Giese; Anja Sander; Colette Dörr-Harim; Markus K Diener; Peter Schemmer
Journal:  BMC Surg       Date:  2014-09-01       Impact factor: 2.102

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.